For example, a combination therapy consisting of anti-EGFR monoclonal antibodies and autophagy inhibitors would represent a multi-pronged approach that could be developed into an active therapeutic strategy in metastatic colorectal cancer patients [29]. Here, EGFR is linked to metastatic colorectal cancer.